Rifasutenizol-Based Triple Therapy Versus Bismuth Plus Clarithromycin Triple Therapy for First-Line Helicobacter pylori Eradication: Analysis of the EVEREST-HP Phase 3 Trial in China
Highlights
- Rifasutenizol (TNP-2198), a novel antimicrobial with dual mechanism, shows high efficacy against H. pylori, including resistant strains.
- In the EVEREST-HP phase 3 trial, rifasutenizol-based triple therapy (RTT) achieved a 92.0% eradication rate, non-inferior to bismuth plus clarithromycin-based triple therapy (BCTT) at 87.9%.
- RTT demonstrated a better safety and tolerability profile, with significantly fewer treatment-emergent adverse events, notably reduced taste perversion compared to BCTT.
- All cultured H. pylori isolates were susceptible to rifasutenizol, highlighting its potential role in overcoming clarithromycin resistance.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.